Dokter terbaik untuk pengobatan Tumor Wilms (Nefroblastoma) di luar negeri — Halaman 2

Dr. Raanan Berger adalah Direktur Pusat Kanker di Sheba Medical Center. Beliau masuk dalam daftar "Dokter Terbaik" Forbes Israel pada tahun 2025. Dr. Berger berspesialisasi dalam onkologi genitourinari dan melakukan radioterapi pada tumor prostat yang kompleks. Beliau menyelesaikan fellowship pascadoktoral di Dana-Farber/Harvard Cancer Institute.

• Memimpin unit penelitian klinis yang berfokus pada onkologi molekuler.
• Penulis bersama lebih dari 20 makalah yang ditinjau sejawat tentang kanker prostat dan mutasi BRCA.
• Anggota American Society of Clinical Oncology (ASCO).
• Melakukan terapi sistemik dan radioterapi di rumah sakit yang masuk dalam peringkat 10 besar dunia.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Murat Cakar adalah Kepala Bedah Anak di Universitas İstinye dan Universitas Aydın. Beliau berfokus pada penyakit toraks neonatal, kondisi perut, dan penggantian atresia esofagus. Dr. Cakar menangani kanker anak yang kompleks, termasuk tumor Wilms dan neuroblastoma. Beliau berpraktik di Liv Hospital Topkapı, fasilitas universitas dengan 33 departemen medis.

• Menjabat sebagai kepala departemen di dua universitas medis besar di Turki.
• Menangani kondisi neonatal seperti hernia diafragma dan penyakit bedah toraks.
• Anggota Asosiasi Ahli Bedah Anak Turki dan Asosiasi Urologi Anak.
• Pernah menjabat sebagai manajer pendiri dan kepala operasi laboratorium di Rumah Sakit Universitas Karabük.

Dr. Mahmoud M. El Zembely mengepalai departemen onkologi anak di Shefaa Al Orman Cancer Center. Beliau adalah spesialis onkologi anak dan hematologi ganas. Dr. El Zembely menyelesaikan fellowship klinis dalam transplantasi sumsum tulang anak di Seattle Cancer Care Alliance. Beliau menangani berbagai jenis kanker anak, termasuk leukemia, limfoma, dan neuroblastoma.

• Menangani semua jenis leukemia anak, serta limfoma Hodgkin dan non-Hodgkin.
• Menangani tumor padat seperti nefroblastoma, rhabdomyosarcoma, dan kanker anak yang langka.
• Melakukan transplantasi sumsum tulang alogenik dan autologus untuk pasien anak.
• Bekerja di pusat yang terakreditasi ESMO yang menangani 6.000 pasien setiap tahunnya.

Prof. Miriam Ben-Harush adalah ahli onkologi anak yang diakui secara internasional, dihormati oleh Asosiasi Medis Dunia sebagai salah satu dokter paling peduli di dunia.

• Direktur Divisi Pediatri di Rumah Sakit Anak Ruth Rappaport
• Spesialis Onkologi Anak dan Transplantasi Sumsum Tulang
• Penerima Chevalier de la Legion d'Honneur di Prancis
• Anggota kelompok onkologi anak di AS dan Eropa

26 tahun spesialis onkologi anak – Dr. Apak memimpin Divisi Hematologi dan Onkologi Anak di Universitas Istanbul-Cerrahpaşa.

• Pakar transplantasi sumsum tulang dan terapi sel CAR-T
• Telah menerbitkan 75 makalah internasional tentang onkologi anak
• Asisten editor untuk jurnal Turkish Pediatrics Archives
• Saat ini menjadi spesialis hematologi dan onkologi anak di Rumah Sakit Universitas Biruni

Dr. Omer Dogru adalah spesialis hematologi dan onkologi anak dengan pengalaman lebih dari 20 tahun dalam menangani kanker pada anak.

• Mengambil spesialisasi hematologi & onkologi anak di Universitas Istanbul
• Bekerja di rumah sakit anak terkemuka termasuk Diyarbakır
• Menjadi anggota dari European Bone Marrow Transplantation society
• Menjalani pelatihan dalam prosedur transplantasi sumsum tulang

31 tahun spesialis onkologi anak – Dr. Lopez Ibor memimpin Unit Hematologi & Onkologi Anak di HM Hospitales, berfokus pada anak-anak dengan kanker berat.

• Kepala Unit Hematologi & Onkologi Anak sejak 2006
• Onkolog anak dengan pelatihan fellowship di University of Maryland
• Konsultan untuk WHO dan UNESCO mengenai kesehatan anak
• Pendiri yayasan yang mendukung anak-anak selama perawatan kanker

Prof. Dr. Suna Emir lulus dari Fakultas Kedokteran Universitas Hacettepe pada tahun 1989. Beliau menyelesaikan residensi pediatri di Universitas Hacettepe dari tahun 1990 hingga 1995. Pada tahun 2001, beliau menyelesaikan subspesialisasi onkologi anak di Institut Onkologi Universitas Hacettepe. Beliau menjadi Profesor Madya pada tahun 2004. Dari tahun 2004 hingga 2009, beliau bekerja di Rumah Sakit Pelatihan dan Penelitian Kesehatan dan Penyakit Anak Ankara Dışkapı dan mendirikan Klinik Onkologi Anak di sana. Pada tahun 2009, beliau menjabat sebagai Wakil Kepala Onkologi Anak. Dari tahun 2009 hingga 2016, beliau adalah petugas pelatihan hematologi-onkologi anak di Rumah Sakit Pelatihan dan Penelitian Kesehatan dan Penyakit Anak, Hematologi-Onkologi Ankara. Sejak 2019, beliau telah menjadi Profesor dan anggota fakultas pendiri di bidang Kesehatan dan Penyakit Anak di Universitas Atilim.

Beliau adalah seorang ahli dalam pediatri umum dan hematologi-onkologi anak. Beliau aktif dalam pelatihan residensi dan subspesialisasi. Minat klinisnya meliputi penyakit masa kanak-kanak dari lahir hingga 18 tahun, limfoma, tumor padat, transplantasi sumsum tulang autologus, anemia, gangguan pendarahan, penyakit darah herediter, hemangioma dan tumor jinak lainnya, serta pembesaran kelenjar getah bening.

Lebih dari _doctor_3339_ tahun spesialisasi dalam onkologi anak – Dr. Lopez Ibor memimpin Unit Hematologi dan Onkologi Anak di Rumah Sakit HM Montepríncipe.

• Keahlian dalam mengobati tumor tulang dan otak pada anak-anak
• Terlatih dalam Hematologi dan Onkologi Anak di University of Maryland
• Penulis berbagai publikasi ilmiah nasional dan internasional
• Sebelumnya memimpin Unit Onkologi Anak di Rumah Sakit Universitas Clínica San Rafael

Prof. Metin Demirkaya berspesialisasi dalam onkologi anak dengan pengalaman lebih dari 27 tahun, saat ini berpraktik di Rumah Sakit Medicana Bursa.

• Menyelesaikan residensi onkologi anak di Universitas Bursa Uludag
• Mantan asisten profesor dan lektor kepala di Universitas Bursa Uludag
• Bekerja di Pusat Hematologi, Onkologi, dan Transplantasi Sumsum Tulang Anak GATA
• Anggota departemen onkologi anak di Rumah Sakit Medicana Bursa

Dr. Gaurav Kharya adalah hematolog-onkolog anak yang berspesialisasi dalam transplantasi sumsum tulang di Artemis Hospitals.

• Berspesialisasi dalam mengobati kanker anak, termasuk tumor Wilms
• Keahlian dalam transplantasi sumsum tulang
• Bekerja di Artemis Hospitals, institusi kesehatan terkemuka

Dr. Shruti Kate berspesialisasi dalam tumor pediatrik, termasuk tumor Wilms, dengan pelatihan dari Tata Memorial Hospital – pusat kanker terkemuka di India.

• Pakar dalam imunoterapi dan terapi metronomik untuk kanker stadium lanjut
• Anggota ASCO, ESMO, dan perkumpulan onkologi bergengsi lainnya
• Mempresentasikan penelitian kanker paru-paru di World Conference on Lung Cancer
• Bekerja di HCG Manavata Cancer Centre dengan pengalaman onkologi yang komprehensif

Kepala Departemen Onkologi Anak di Charité – Universitätsmedizin Berlin, berspesialisasi dalam kanker anak seperti tumor Wilms.

• Memimpin tim onkologi anak yang berdedikasi
• Berfokus pada rencana perawatan komprehensif untuk pasien muda
• Bekerja di salah satu rumah sakit universitas terkemuka di Eropa